# Black Diamond Therapeutics

Source: https://onco.cc/companies/black-diamond-therapeutics/  
OnCo record `black-diamond-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Black Diamond Therapeutics designs cancer pills that hit whole families of mutations in a growth protein at once. Its lead drug, silevertinib, targets mutated EGFR in lung cancer and brain tumours.

## Summary

Black Diamond Therapeutics is a Cambridge, Massachusetts precision oncology company whose MAP platform designs small molecules that inhibit families of oncogenic mutations. Its lead candidate, silevertinib (formerly BDTX-1535), is a brain-penetrant, mutant-selective EGFR inhibitor: the company lists phase 2 studies in first-line and second/third-line EGFR-mutant non-small cell lung cancer (with FDA Fast Track designation for C797S-positive patients and final phase 2 data at ASCO 2026) and a randomised phase 2 trial in newly diagnosed glioblastoma initiated in the second quarter of 2026. BDTX-4933, a RAF inhibitor for RAF/RAS-mutant solid tumours, has been licensed to Servier, and BDTX-4876 (FGFR2/3) is preclinical. The company completed its Nasdaq IPO in February 2020, raising 231.3 million US dollars gross.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Cambridge, MA
- Type: biotech
- Website: https://blackdiamondtherapeutics.com/
- Ticker: BDTX

## Notes

- Founding year not sourced. The 'braf' target tag reflects the RAF programme BDTX-4933 (RAF/RAS-mutant tumours) rather than a BRAF-specific claim.

## Sources

- Official website: https://blackdiamondtherapeutics.com/
- Pipeline: https://blackdiamondtherapeutics.com/pipeline-programs/pipeline
- Q4 2019 results noting IPO proceeds (SEC exhibit): https://www.sec.gov/Archives/edgar/data/1701541/000170154120000008/bdtx-exhibit991.htm

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BRAF](https://onco.cc/targets/braf/), [EGFR](https://onco.cc/targets/egfr/), [FGFR2](https://onco.cc/targets/fgfr2/)
- drugs: [Silevertinib](https://onco.cc/drugs/silevertinib/)
- trials: [Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations](https://onco.cc/trials/nct05256290/), [Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII](https://onco.cc/trials/nct07326566/)
- companies: [Casdin Capital](https://onco.cc/companies/casdin-capital/)
- roadmaps: [Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall](https://onco.cc/roadmaps/targeted-therapy-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/black-diamond-therapeutics.json